The First DNA Shot of Its Kind Gets the OK, Plus AMD Undercuts Nvidia | Tech Arcade Podcast
The FDA has given accelerated approval to Inovio's Voceryq, the first plasmid DNA immunotherapy approved in the US, for a rare airway disease that can mean several throat surgeries a year. We explain how it works, what the 27% trial result means and the catches. Then: a SemiAnalysis benchmark suggests Nvidia's B200 can cost about 2.3 times as much per token as AMD's MI355X to serve the same AI model, and why that comes with big caveats.
Full story: https://www.techarcade.io/the-fda-just-approved-america-s-first-dna-injection-immunotherapy-and-inovio-s-stock-tripl/
Full story: https://www.techarcade.io/nvidia-s-b200-costs-2-3x-more-than-amd-s-mi355x-to-serve-the-same-ai-model/
Sources
https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis
https://www.stocktitan.net/news/INO/inovio-announces-fda-accelerated-approval-of-voceryqtm-an-6o64cas5rrns.html
https://www.hcplive.com/view/voceryq-gains-fda-accelerated-approval-for-recurrent-respiratory-papillomatosis
https://s21.q4cdn.com/283306112/files/doc_news/INOVIO-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Highlights-2026.pdf
https://www.drugs.com/news/fda-approves-papzimeos-adults-recurrent-respiratory-papillomatosis-126350.html
https://finance.biggo.com/news/48d5a3a0-2a1a-49cf-8257-3ab4c1e8c3d5
https://inferencex.semianalysis.com/compare-per-dollar/kimi-k3-b200-vs-mi355x
https://inferencex.semianalysis.com/blog/mi355x-glm5-fp8-sglang-40-cheaper-than-b200
https://fourweekmba.com/ai-nvidia-b200-costs-up-to-2-3x-amd-mi355x-per-kimi-k3-token/
https://aiweekly.co/alerts/amd-mi355x-up-to-46-cheaper-than-gb200-nvl72-on-kimi-k3-28t
Where sources differ: reports of Inovio's share jump range from about 215% to more than 300%, so the episode says "more than two hundred percent".
More at https://www.techarcade.io
#techarcade #biotech #FDA #Nvidia #AMD


